CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Merrimack Pharmaceuticals, Inc. - MACK CFD

14.71
0%
  • Summary
  • Historical Data
  • Events
Trading сonditions
Spread 0.11
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 14.71
Open* 14.71
1-Year Change* 21.87%
Day's Range* 14.7 - 14.79
52 wk Range N/A
Average Volume (10 days) N/A
Average Volume (3 months) N/A
Market Cap N/A
P/E Ratio N/A
Shares Outstanding N/A
Revenue N/A
EPS N/A
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 14.71 -0.02 -0.14% 14.73 14.79 14.70
Mar 27, 2024 14.71 0.05 0.34% 14.66 14.74 14.66
Mar 26, 2024 14.67 -0.01 -0.07% 14.68 14.76 14.67
Mar 25, 2024 14.68 0.00 0.00% 14.68 14.86 14.67
Mar 22, 2024 14.73 0.08 0.55% 14.65 14.79 14.64
Mar 21, 2024 14.64 -0.01 -0.07% 14.65 14.72 14.63
Mar 20, 2024 14.64 0.00 0.00% 14.64 14.71 14.62
Mar 19, 2024 14.64 -0.01 -0.07% 14.65 14.72 14.64
Mar 18, 2024 14.66 0.00 0.00% 14.66 14.71 14.64
Mar 15, 2024 14.68 0.08 0.55% 14.60 14.71 14.60
Mar 14, 2024 14.62 -0.01 -0.07% 14.63 14.65 14.60
Mar 13, 2024 14.62 0.01 0.07% 14.61 14.67 14.60
Mar 12, 2024 14.60 -0.01 -0.07% 14.61 14.67 14.55
Mar 11, 2024 14.58 -0.09 -0.61% 14.67 14.69 14.58
Mar 8, 2024 14.68 0.01 0.07% 14.67 14.77 14.64
Mar 7, 2024 14.70 0.05 0.34% 14.65 14.73 14.64
Mar 6, 2024 14.66 0.01 0.07% 14.65 14.68 14.63
Mar 5, 2024 14.64 -0.02 -0.14% 14.66 14.68 14.63
Mar 4, 2024 14.64 -0.03 -0.20% 14.67 14.72 14.64
Mar 1, 2024 14.67 0.03 0.20% 14.64 14.72 14.64

Merrimack Pharmaceuticals, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Merrimack Pharmaceuticals, Inc. Company profile

About Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Merrimack Pharmaceuticals Inc revenues was not reported. Net loss increased 3% to $2M. Higher net loss reflects Gain on sale of assets decrease of 93% to $144K (income), Interest income decrease of 61% to $19K (income), Other income (expense), net decrease from $18K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.14 to -$0.15.

Equity composition

Common Stock $0.01 Par, 02/12, 200M auth., 94,756,679 issd. Insiders own 9.59%. IPO:TBA

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.62 Price
-2.140% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

BTC/USD

69,751.05 Price
-1.180% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading